
Acorda Therapeutics has announced that it is terminate development of its Parkinson’s therapy tozadenant after five deaths were reported as …
Acorda Therapeutics announced that they were unable to continue development of the drug, dalfampridine, due to lack of efficacy in …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

